Preferences for the First-Line Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer

Bristol-Myers Squibb1 site in 1 country501 target enrollmentDecember 9, 2021

ConditionsCarcinoma, Non-Small-Cell Lung

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Carcinoma, Non-Small-Cell Lung
Sponsor: Bristol-Myers Squibb
Enrollment: 501
Locations: 1
Primary Endpoint: Set of relative preference weights for all attribute levels included in the Discrete Choice Experiment (DCE)
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this observational study is to determine participants' preferences for outcomes associated with first-line treatment of advanced/metastatic Non-Small Cell Lung Cancer (NSCLC) using a discrete-choice experiment (DCE).

Registry

clinicaltrials.gov

Start Date

December 9, 2021

End Date

January 4, 2023

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Bristol-Myers Squibb

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•The following is the inclusion criteria for pretest interviews and final online survey.
•Participants:
•Must be 18 years of age or older
•Must be a US resident.
•Lung cancer participants with a physician diagnosis of NSCLC. Global Perspectives will be involved to suggest alternative strategies to a physician-confirmed diagnosis to ensure that actual cancer participants are recruited.